<DOC>
	<DOCNO>NCT02022202</DOCNO>
	<brief_summary>The purpose research study well understand reason breast cancer destroy standard chemotherapy . This information use develop new good cancer therapy .</brief_summary>
	<brief_title>Breast Cancer Genome Guided Therapy Study ( BEAUTY )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Age ≥18 year . Histological confirmation invasive breast cancer . Confirmation breast cancer lesion ≥ 1.5 cm size clinical ( physical examination measurement ) radiographic criterion ( mammogram , ultrasound MRI ) ipsilateral breast . Note : Benign breast disease , LCIS DCIS contralateral breast allow . Contralateral invasive breast cancer allow disease clinically low stage high stage lesion study lesion biopsy tissue sample . Note : Disease axilla eligible . Note : Patients contraindication inability MRI may still enrol study participate MRI study specific time point . Note : For patient bilateral disease high clinical stage disease study lesion undergo study biopsy tissue sample surgery contralateral lesion NOT undergo research biopsy tissue sample . Men woman begin neoadjuvant chemotherapy treatment Stage IIII Her 2 negative breast cancer paclitaxel follow either combination 5fluorouracil , epirubicin cyclophosphamide ( FEC ) combination doxorubicin cyclophosphamide ( AC ) . OR Men woman begin neoadjuvant chemotherapy treatment Stage IIII Her 2 positive breast cancer paclitaxel follow either combination 5fluorouracil , epirubicin cyclophosphamide ( FEC ) combination doxorubicin cyclophosphamide ( AC ) . MC1137 Trastuzumab give concurrently taxane portion give concurrently FEC ( AC ) discretion medical oncologist . Note : Her2 positive disease define : HER2 score 3+ IHC HER2 gene amplification FISH . Provide inform write consent . Willing return Mayo Clinic Rochester , MN , Mayo Clinic Arizona , Mayo Clinic Florida image correlative , surgery , followup . Willing provide blood sample correlative research purpose . Willing provide tissue sample correlative research purpose . ECOG Performance Status ≤ 2 . Receiving investigational agent would consider treatment primary neoplasm . Other active malignancy ≤ 5 year prior registration . EXCEPTIONS : Nonmelanotic skin cancer carcinomainsitu cervix . Note : If history prior malignancy , must receive treatment cancer . Patients plan receive neoadjuvant chemotherapy . Biopsy proven Stage IV disease . Patients pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>